Skip to main content Skip to main navigation menu Skip to site footer
logo Mediterranean Journal of Hematology and Infectious Diseases

eISSN 2035-3006

  • Home
  • About the Journal
  • Editorial Board
  • Current
  • Archives
  • Announcements
  • Register
  • Login
  • Journal Statistics
  • Search
  • Contact
  • Announcements

Editor-in-Chief: Giuseppe Leone | Italy

2.3
Impact Factor 2025
3.2
CiteScore 2025
2.3
Impact Factor 2025
3.2
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

    Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti
    e2014005
    2014-01-02
    https://doi.org/10.4084/mjhid.2014.005
    3454
    PDF: 1510
    HTML: 4078
  • IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

    Tomasz Sacha
    e2014007
    2013-12-31
    https://doi.org/10.4084/mjhid.2014.007
    4933
    PDF: 2913
    HTML: 2337
  • PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

    matteo molica, elisabetta abruzzese, massimo breccia
    e2020062
    2020-09-12
    https://doi.org/10.4084/mjhid.2020.062
    4057
    PDF: 1649
    HTML: 795
  • TYROSINE KINASE INHIBITORS AND INTERFERON

    Maria Dimou, Panagiotis Panagiotidis
    e2014006
    2014-01-02
    https://doi.org/10.4084/mjhid.2014.006
    2933
    PDF: 1466
    HTML: 3095
    Cover Letter: 231
  • NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms

    Gianfranco Catalano, Pasquale Niscola, Cristina Banella, Daniela Diverio, Malgorzata Monika Trawinska , Stefano Fratoni, Rita Iazzoni, Paolo de Fabritiis, Elisabetta abruzzese, Nelida Ines Noguera
    e2020083
    2020-10-27
    https://doi.org/10.4084/mjhid.2020.083
    1784
    PDF: 1231
    HTML: 323
  • MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

    Ibrahim C. Haznedaroglu
    e2014009
    2013-12-31
    https://doi.org/10.4084/mjhid.2014.009
    4111
    PDF: 1574
    HTML: 9247
    Untitled: 295
    Untitled: 201
    Untitled: 188
    Untitled: 182
    Untitled: 203
    Untitled: 360
  • SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

    Massimo Breccia, Giuliana Alimena
    e2014003
    2014-01-02
    https://doi.org/10.4084/mjhid.2014.003
    3347
    PDF: 1254
    HTML: 3525
  • TYROSINE KINASE INHIBITORS AND PREGNANCY

    Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti
    e2014028
    2014-04-07
    https://doi.org/10.4084/mjhid.2014.028
    3730
    PDF: 1707
    HTML: 2689
  • OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

    Mohamed Amine BEKADJA
    e2017062
    2017-10-25
    https://doi.org/10.4084/mjhid.2017.062
    2950
    PDF: 749
    HTML: 918
  • FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY

    Jyotsna Kapoor, Narendra Agrawal, Rayaz Ahmad, Sanjeev Kumar Sharma, Anshul Gupta, Dinesh Bhurani
    e2015013
    2015-02-12
    https://doi.org/10.4084/mjhid.2015.013
    2005
    PDF: 1105
    HTML: 1815
  • OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

    Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien
    e2015003
    2015-01-01
    https://doi.org/10.4084/mjhid.2015.003
    2319
    PDF: 1085
    HTML: 2025
    Characteristic of study group: 217
  • DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia

    Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu
    e2023008
    2023-01-01
    https://doi.org/10.4084/MJHID.2023.008
    1420
    PDF: 1289
    HTML: 515
  • DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

    Ibrahim C. Haznedaroglu
    e2015014
    2015-12-02
    https://doi.org/10.4084/mjhid.2015.014
    277764
    PDF: 1844
    HTML: 3897
  • LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

    Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
    e2011021
    2011-05-16
    https://doi.org/10.4084/mjhid.2011.021
    1708
    PDF: 824
    HTML: 874
    jdoe, table 2 infections CML .doc: 212
    jdoe, table 1 infections CML .doc: 200
  • SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA

    Naveen Gupta, Manoranjan Mahapatra, Tulika Seth, Seema Tyagi, Sudha Sazawal, Renu Saxena
    e2021004
    2021-01-01
    https://doi.org/10.4084/mjhid.2021.004
    1871
    PDF: 595
    HTML: 287
  • First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience

    Dangui Chen
    e2026066
    2026-09-01
    https://doi.org/10.4084/MJHID.2026.066
    0
    PDF: 0
    Html: 0
  • Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature

    Ekaterina Chelysheva, Sergey Aleshin, Evgenia Polushkina, Roman Shmakov, Igor Shokhin, Ghermes Chilov, Anna Turkina
    e2018027
    2018-05-01
    https://doi.org/10.4084/mjhid.2018.027
    3244
    PDF: 1035
    HTML: 410
  • Coexistence of P190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: a case report

    najmaldin saki, Mohammad Seghatoleslami, Neda Ketabchi, Alireza Ordo, Javad Mohammadi-Asl, Neda Golchin
    e2016002
    2016-01-01
    https://doi.org/10.4084/mjhid.2016.002
    3134
    PDF: 884
    HTML: 2504
  • Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review

    Toshifumi Takahashi
    e2020005
    2020-01-01
    https://doi.org/10.4084/mjhid.2020.005
    1857
    PDF: 1287
    HTML: 361
  • Penile Abscess Caused by Salmonella enteritidis Bacteraemia in an Adolescent with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

    YIH HOONG LEE, SHAN KAI ING, KIAT JENG LIEW, JIAN YUAN CHENG, ANDREW KEAN WEI CHANG, TZE SHIN LEONG
    e2026058
    2026-06-30
    https://doi.org/10.4084/MJHID.2026.058
    172
    PDF: 148
    HTML: 96
  • IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

    Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica
    e2021062
    2021-10-29
    https://doi.org/10.4084/MJHID.2021.062
    1298
    PDF: 520
    HTML: 196
  • Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

    Domenico Santorsola, Elisabetta Abruzzese
    e2015020
    2015-02-12
    https://doi.org/10.4084/mjhid.2015.020
    2097
    PDF: 1251
    HTML: 1661
  • CD56+/CD38+ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia

    Alessandro Laganà, Matteo Breccia, Loredana Elia, Emilia Scalzulli, Maria Laura Bisegna, Claudia Ielo, Sonia Buffolino, Attilio Di Lascio, Concetta Anna Germano, Stefania Intoppa, Maria Laura Milani, Maurizio Martelli, Massimo Breccia, Maria Stefania De Propris
    2026-04-30
    https://doi.org/10.4084/MJHID.2026.049
    265
    PDF: 297
    Suppl. Files: 60
    HTML: 59
  • Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

    Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà
    e2026013
    2026-01-01
    https://doi.org/10.4084/MJHID.2026.013
    639
    PDF: 550
    Html: 91
  • DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML

    Istemi SERIN, Mustafa PEHLIVAN, Kursat OZDILLI, Fatma OGUZ SAVRAN, Gaye TOMATIR, Sacide PEHLIVAN
    e2021020
    2021-02-26
    https://doi.org/10.4084/mjhid.2021.020
    1159
    PDF: 468
    HTML: 276
  • PROGNOSTIC VALUE OF PROTEASE ACTIVATED RECEPTOR-1 IN EGYPTIAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

    Adel Abd Elhaleim Hagag
    e2014029
    2014-04-06
    https://doi.org/10.4084/mjhid.2014.029
    1392
    PDF: 826
    HTML: 2372
  • Interstitial pneumonia triggered by H1N1 influenza A virus as the initial presentation of chronic myeloid leukemia

    Zhan Su, Feng Wang
    e2025063
    2025-08-31
    https://doi.org/10.4084/MJHID.2025.063
    919
    PDF: 531
    HTML: 236
    Suppl. Files: 339
  • COMPARATIVE EVALUATION OF BONE MARROW ASPIRATE WITH TREPHINE BIOPSY IN HEMATOLOGICAL DISORDERS AND DETERMINATION OF OPTIMUM TREPHINE LENGTH IN LYMPHOMA INFILTRATION

    Surbhi Goyal, Usha Rani Singh, Usha Rusia
    e2014002
    2013-12-31
    https://doi.org/10.4084/mjhid.2014.002
    2082
    PDF: 1100
    HTML: 51869
  • Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

    Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena
    e2016016
    2016-02-20
    https://doi.org/10.4084/mjhid.2016.016
    2959
    PDF: 717
    HTML: 1955
    figure 1: 188
    figure 2: 190
  • SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19

    Elisabetta Abruzzese, Luigia Luciano, Francesco D'Agostino, Malgorzata Monika Trawinska, Fabrizio Pane, Paolo de Fabritiis
    e2020031
    2020-04-27
    https://doi.org/10.4084/mjhid.2020.031
    3352
    PDF: 1579
    HTML: 474
  • THE PROGNOSTIC SIGNIFICANCE OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM IN EGYPTIAN CHRONIC MYELOID LEUKEMIA THE PROGNOSTIC SIGNIFICANCE OF TET2 SINGLE NUCLEOTIDE POLYMORPHISM IN EGYPTIAN CHRONIC MYELOID LEUKEMIA

    Enas A Dammag, Nahla A.M. Hamed, Professor, Nabil A El Halawani, Professor, Heba S Kassem, Professor, Mona W Ayad, Professor
    e2020004
    2020-01-01
    https://doi.org/10.4084/mjhid.2020.004
    2123
    PDF: 1010
    HTML: 324
1 - 31 of 31 items
Make a Submission

Links

  • Editorial Board
  • Alert me!
  • Advertising
  • Scopus
  • DOAJ
  • Article Processing Charge

Information

  • For Readers
  • For Authors
  • For Librarians

Indexing

  • OpenAlex
  • Analytics

PubMed

MJHID CiteScore by Scopus

Clarivate Analytics

this journal is covered
by Clarivate Analytics

 

The Mediterranean Journal of Hematology and Infectious Diseases has been selected for coverage in Clarivate Analytics products and services. Beginning with V. 7 (1) 2015.

AskBisht

Indexed in AskBisht.com

Facebook

FOLLOW US

MJHID in EuroPub Database

EuroPub

CLL UpDate

Keywords

Mediterranean Journal of Hematology and Infectious Diseases

is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. The MJHID is indexed and abstracted in Science Citation Index Expanded and Journal Citation Reports/InCites beginning with V. 7 (1) 2015.

eISSN: 2035-3006

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.